Trial Profile
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Vimseltinib (Primary)
- Indications Giant cell tumour of tendon sheath; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 06 Feb 2024 According to Deciphera Pharmaceuticals media release, the company expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
- 08 Jan 2024 According to a Deciphera Pharmaceuticals media release, data from this trial will be presented in the second half of 2024.
- 30 Oct 2023 According to a Deciphera Pharmaceuticals media release, updated results from this study will be presented at the Connective Tissue Oncology Society 2023 Annual Meeting in Dublin, Ireland on November 1-4, 2023.